Enzychem Lifesciences엔지켐생명과학
183490 · KOSDAQ · ₩183490 · 엔지켐생명과학
₩990 ₩0 (0.00%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩68B | ₩77B | ₩76B | ₩27B | ₩23B |
| Cost of sales | ₩64B | ₩73B | ₩72B | ₩24B | ₩23B |
| Gross profit | ₩3.4B | ₩4.3B | ₩4.3B | ₩2.4B | ₩287M |
| Operating income | −₩14B | −₩13B | −₩14B | −₩15B | −₩21B |
| Net income | −₩18B | −₩22B | −₩9.4B | −₩25B | −₩28B |
| Net income to shareholders | −₩18B | −₩22B | −₩9.3B | −₩25B | −₩28B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩149B | ₩182B | ₩212B | ₩248B | ₩133B |
| Current assets | ₩116B | ₩148B | ₩174B | ₩220B | ₩110B |
| Cash and equivalents | ₩7.8B | ₩10B | ₩15B | ₩7.7B | ₩2.8B |
| Total liabilities | ₩9.8B | ₩20B | ₩17B | ₩46B | ₩58B |
| Current liabilities | ₩8.2B | ₩11B | ₩14B | ₩42B | ₩54B |
| Borrowings | ₩4.2B | ₩3.8B | ₩4.4B | ₩37B | ₩52B |
| Total equity | ₩139B | ₩161B | ₩195B | ₩202B | ₩75B |
| Shareholders' equity | ₩138B | ₩160B | ₩194B | ₩202B | ₩75B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩11B | −₩574M | −₩10B | −₩14B | −₩19B |
| Free cash flow | −₩11B | −₩574M | −₩10B | −₩14B | −₩19B |
Consolidated where available. Amounts in won.
Also known as: Enzychem Lifesciences / 엔지켐생명과학 / 183490 / KRX:183490
Source: KRX statistical information